Incidence and Factors of Hepatocellular Carcinoma in Hepatitis C Virus Patients Achieving Sustained Virological Response After Direct-Acting Antiviral Treatment
), Dhaneswara Adhyatama Wicaksono(2), Evy Yunihastuti(3), Arif Masnjoer(4),
(1) Division of Hepatobilliary, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta
(2) Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta
(3) Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta
(4) Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta
Corresponding Author
Abstract
Background: The incidence and risk factors for Hepatocellular Carcinoma (HCC) in Hepatitis C Virus (HCV) patients who have achieved Sustained Virological Response (SVR) after Direct-Acting Antiviral (DAA) therapy are not well established. Considering there are differences in DAA types, virus genotypes, and patient profiles in Indonesia, this study was conducted to assess the incidence and factors influencing HCC in HCV patients after SVR post DAA therapy. The objective of this study to determine the incidence and factors influencing HCC in HCV patients achieving SVR after DAA treatment.
Methods: Retrospective cohort study conducted at Cipto Mangunkusumo National General Hospital, sample of HCV patients had SVR after DAA therapy in 2017 – 2019, followed until 2024. Patients were screened for abdominal ultrasound, alpha-fetoprotein (AFP) and 3-phase abdominal CT scan, if indicated. Descriptive, bivariate analysis with Fisher's exact, and multivariate analysis with logistic regression were conducted.
Results: Among 180 subjects, the incidence and incidence ratio of HCC is 4.4% (0.91/100PY). Significant correlation in bivariate analysis from the variables liver cirrhosis (RR 10.5; CI 95% (1. 32 – 83.5); p = 0.0073) and type 2 DM (RR 8.47; CI 95% (2, 3 – 31.1) p = 0.0048). In multivariate analysis, there was significant correlation from type 2 DM variable (aRR 3.1; CI 95% (0.86 – 3.83); p=0.002).
Conclusion: The incidence of HCC reaches 4.4% of the total population. Type 2 DM has significant correlation with the incidence of HCC in HCV patients who achieve SVR after DAA treatment.
Keywords
References
Jessica Howell AJT. Hepatocellular carcinoma after sustained virologic response: leave no one behind. Gastroenterology. 2017;152(6):1282-4.
D HM. Epidemiology of Hepatitis B and C in Republic of Indonesia. Euroasian J Hepatogastroenterol. 2017;7(1):55-9.
Hasan I, Gani RA, Sulaiman AS, Lesmana C. Konsensus nasional penatalaksanaan hepatitis C di indonesia. 2017.
Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. WHO Guidelines Approved by the Guidelines Review Committee. Geneva2018.
Lee SS, Jeong SH, Jang ES, Kim YS, Lee YJ, Jung EU, et al. Prospective cohort study on the outcomes of hepatitis C virus-related cirrhosis in South Korea. J Gastroenterol Hepatol. 2015;30(8):1281-7.
Denniston MM, Jiles RB, Drobeniuc J, Klevens RM, Ward JW, McQuillan GM, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med. 2014;160(5):293-300.
Gigi E, Lagopoulos VI, Bekiari E. Hepatocellular carcinoma occurrence in DAA-treated hepatitis C virus patients: Correlated or incidental? A brief review. World J Hepatol. 2018;10(9):595-602.
Hu J, Liu K, Luo J. HIV-HBV and HIV-HCV Coinfection and Liver Cancer Development. Cancer Treat Res. 2019;177:231-50.
Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33(4):562-9.
Abbas Z, Abbas M. Factors predicting hepatocellular carcinoma in hepatitis C infection. Hepatoma Research. 2018;4.
Brunot A, Le Sourd S, Pracht M, Edeline J. Hepatocellular carcinoma in elderly patients: challenges and solutions. J Hepatocell Carcinoma. 2016;3:9-18.
Ahumada A, Rayón L, Usón C, Bañares R, Alonso Lopez S. Hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis: Who to screen and for how long? World J Gastroenterol. 2021;27(40):6737-49.
Leal C, Strogoff-de-Matos J, Theodoro C, Teixeira R, Perez R, Guarana T, et al. Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Treated with Direct-Acting Antivirals. Viruses. 2023;15(1).
Shafira., Muhtadi A. Evaluasi kepatuhan pasien hepatitis C periode Juli 2018 - Juli 2019 di instalasi rawat jalan salah satu rumah sakit Kota Bandung. Farmaka. 2020;18.
Carrat F, Fontaine H, Dorival C, Simony M, Diallo A, Hezode C, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet. 2019;393(10179):1453-64.
Abe K, Wakabayashi H, Nakayama H, Suzuki T, Kuroda M, Yoshida N, et al. Factors associated with hepatocellular carcinoma occurrence after HCV eradication in patients without cirrhosis or with compensated cirrhosis. PLoS One. 2020;15(12):e0243473.
Hagiwara H, Ito Y, Ohta T, Nozaki Y, Iwamoto T, Hosui A, et al. Incidence and risk factors of hepatocellular carcinoma in patients with hepatitis C who achieved a sustained virological response through direct-acting antiviral agents among the working population in Japan. JGH Open. 2022;6(6):395-401.
Yang M, Parikh ND, Liu H, Wu E, Rao H, Feng B, et al. Incidence and risk factors of hepatocellular carcinoma in patients with hepatitis C in China and the United States. Sci Rep. 2020;10(1):20922.
Calvaruso V, Cabibbo G, Cacciola I, Petta S, Madonia S, Bellia A, et al. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. Gastroenterology. 2018;155(2):411-21 e4.
Kurniawan J, Teressa M. Insulin use and the risk of hepatocellular carcinoma: insights and implications. Indones J Intern Med. 2024;56:107 - 13.
Masuzaki R, Tateishi R, Yoshida H, Goto E, Sato T, Ohki T, et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology. 2009;49(6):1954-61.
KemenkesRI. Pedoman nasional pelayanan kedokteran tata laksana karsinoma sel hati pada dewasa. In: KemenkesRI, editor. Jakarta: KemenkesRI; 2022.
Article Metrics
Abstract View
: 52 times
Download : 5 times
DOI: 10.24871/253202424-31
Refbacks
- There are currently no refbacks.
